# EDGAR Filing Document

**Accession Number:** 0001786720
**File Stem:** 0001610717-26-000134
**Filing Date:** 2026-3
**Character Count:** 9025
**Document Hash:** faabae62531aeca7eca8e67eacc2a45a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001610717-26-000134.hdr.sgml**: 20260325

**ACCESSION NUMBER**: 0001610717-26-000134

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260323

**FILED AS OF DATE**: 20260325

**DATE AS OF CHANGE**: 20260325

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Saxonov Serge
- **CENTRAL INDEX KEY:** 0001786720

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39035
- **FILM NUMBER:** 26793509

**MAIL ADDRESS:**
- **STREET 1:** 10X GENOMICS, INC.
- **STREET 2:** 6230 STONERIDGE MALL ROAD
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 10x Genomics, Inc.
- **CENTRAL INDEX KEY:** 0001770787
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 455614458
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 6230 STONERIDGE MALL ROAD
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588
- **BUSINESS PHONE:** (925) 401-7300

**MAIL ADDRESS:**
- **STREET 1:** 6230 STONERIDGE MALL ROAD
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 10X Genomics, Inc.
- **DATE OF NAME CHANGE:** 20190315

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Saxonov Serge<br><sub>(Last) (First) (Middle)</sub><br>10X GENOMICS, INC.<br>6230 STONERIDGE MALL ROAD<br><sub>(Street)</sub><br>PLEASANTON, CA 94588<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-23 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>10x Genomics, Inc. [ TXG ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class A Common Stock | 2026-03-23 |  | S<sup>(1)</sup> |  | 10000 | D | 19.1297<sup>(2)</sup> | 1177273<sup>(3)</sup> | D |  |
| Class A Common Stock | 2026-03-24 |  | S<sup>(1)</sup> |  | 5000 | D | 19.5223<sup>(4)</sup> | 1172273 | D |  |
| Class A Common Stock |  |  |  |  |  |  |  | 27 | I | See footnote<sup>(5)</sup> |
| Class A Common Stock |  |  |  |  |  |  |  | 213250 | I | See footnote<sup>(6)</sup> |
| Class A Common Stock |  |  |  |  |  |  |  | 71644<sup>(3)</sup> | I | See footnote<sup>(7)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Class B Common Stock | <sup>(8)</sup> |  |  |  |  |  |  | <sup>(8)</sup> | <sup>(8)</sup> | Class A Common Stock | 1100927 |  | 1100927<sup>(9)</sup> | D |  |
| Class B Common Stock | <sup>(8)</sup> |  |  |  |  |  |  | <sup>(8)</sup> | <sup>(8)</sup> | Class A Common Stock | 180938 |  | 180938<sup>(9)</sup> | I | See footnote<sup>(10)</sup> |
| Class B Common Stock | <sup>(8)</sup> |  |  |  |  |  |  | <sup>(8)</sup> | <sup>(8)</sup> | Class A Common Stock | 1750000 |  | 1750000 | I | See footnote<sup>(11)</sup> |

---

### Footnotes:

(1) The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

(2) This transaction was executed in multiple trades at prices ranging from $18.78 to $19.41, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

(3) Reflects the transfer by the Reporting Person of 13,644 shares of Class A Common Stock to the Y/S Pot Trust on March 3, 2026.

(4) This transaction was executed in multiple trades at prices ranging from $19.49 to $19.59, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

(5) The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

(6) The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

(7) The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

(8) Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

(9) Reflects the transfer by the Reporting Person of 91,113 shares of Class B Common Stock to the Sirius Trust on March 3, 2026.

(10) The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee.

(11) 250,000 shares are held by each of Polaris 2018 Irrevocable Trust, Antares 2018 Irrevocable Trust, Arcturus 2018 Irrevocable Trust, FLY 2018 Irrevocable Trust, LY 2018 Irrevocable Trust, MS 2018 Irrevocable Trust and NS 2018 Irrevocable Trust, of which the Reporting Person is the sole trustee.

**Signature:** /s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov  
**Date:** 2026-03-25

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**